Articles On Neuren Pharmaceuticals (ASX:NEU)

Trofinetide is an investigational drug developed by Neuren designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.

04 Mar 2020 - Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals (ASX:NEU) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) d…

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

Drug development is an extensive process and includes drug discovery & development, pre-clinical and clinical research and FDA approvals, including Post-Market Drug Safety Monitoring. The first and the most essential step of drug devel...

Australian health care sector is booming with strong growth prospects amid global trade worries and market volatility. Being dynamic and lucrative sector, it catches investors’ attention often. When the share price of a company is multiplie...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

One of the oldest tropes in journalism is the miracle cure. Startup Daily is old enough to remember when Filipino faith healers were all the rage in the 1980s – think Penn & Teller meets House. More recently, there was US blood-testing...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

Health stocks are reckoned amid those that can rapidly grow from a single line of product with small market capitalisation to a company worth over billions. Regarded as one of the most exciting sectors of the stock market, health stocks hol...

Australian health care sector is growing potentially by generating significant profits in a short period, and that is something the investors are also closely monitoring. Australia’s public healthcare system is one of the world’s best, join...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted an orphan drug designation by the US Food and Drug Administration. Drug candidate NNZ-2591 has previously de...

The Federal agency of the United States Department of Health and Human Services, US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591. Neuren’s NNZ-2591 drug is used in th...

Agri-tech business Roots Sustainable Agricultural Technologies (ASX:ROO) says its crop-cooling technology continues to gain traction with commercial cannabis producers. The Israeli-based company released results from the operation of its Ro...

US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591 for the treatment of Angelman syndrome. Orphan Drug designation is a special status that the FDA may grant to a drug to...

The S&P/ASX 200 index looks set to finish the week on a high on Friday. In afternoon trade the benchmark index is up 0.65% to 6,761.1 points. Four shares that have failed to follow the market higher today are listed below. Here’s why t...

Even though the stock markets are sensitive to the global macro-economic parameters, in the present scenario, the investors need to maintain their focus towards the US corporate earnings. The companies, generally, provide information on how...

Healthcare Healthcare sector comprises of the companies that offer medical services, producing medical equipment or medicines. These companies also give medical insurance to the patients. In Australia, the funding of healthcare is taken ca...

In the never-ending battle against bacteria, Next Science (ASX:NSX) has adopted a ‘take no prisoners’ approach in eradicating the bodily bolt holes in which these pathogens congregate and quietly multiply. With a suite of four approved prod...